3Derm Systems
Boston
About 3Derm Systems
3Derm is a cost-effective, skin imaging system that allows non-dermatologists to take clinical-quality 3D skin images remotely. Two million Americans develop skin cancer every year. With 3Derm, dermatologists can review images taken at medical kiosks and other referral sites to efficiently monitor high volumes of patients’ lesions while reserving in-office appointment times for those patients whose images indicate a more alarming condition. 3Derm cuts down on wait times reduces healthcare spending and save lives. Two million Americans develop skin cancer every year. Patients currently monitor their skin through routine dermatology appointments, which are scheduled as frequently as six times per year for high-risk cases. These are both expensive and inconvenient. 3Derm Systems is developing a low-cost skin monitoring solution that allows patients to take clinical-quality 3D images from the comfort of their own homes. Dermatologists can use the uploaded images to efficiently monitor high volumes of patients' lesions while reserving in-clinic appointment times for patients whose images indicate a more alarming condition. 3Derm aims to revolutionize the field of teledermatology by providing greater access to dermatological care. Some patients use handheld digital cameras or apps to take and send images via teledermatology. 3Derm allows patients to keep their local dermatologist instead of using a telemedicine service and uses clinical quality features that ensure every image maximizes diagnostic usefulness for both the patient and the physician.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $3.9M
- Funding stage: M&A
- Last round: Grant (Jan 2019)
- Website: 3derm.com
- Phone: 617-246-0957
Industries & Categories
3D Technology, Biotechnology, Health Care, Health Diagnostics, Image Recognition
Social Profiles
Canonical: https://fsome.com/organization/3derm-systems-173986 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.